Stem Cell Gold Rush
By Jesse Reynolds,
Hartford Courant
| 08. 20. 2006
State Board Rife With Conflicts
Connecticut and a handful of other states are funding human embryonic stem cell research on their own, in reaction to the federal stalemate. Unfortunately, there are signs that Connecticut's $100 million program is rushing forward in a reckless and haphazard way, risking not just millions of taxpayer dollars but the reputation of a line of research that could alleviate suffering.
Although last summer's law creating the program has some admirable points, its key flaw is the composition of the grant-awarding committee. The law's requirements mean that two-thirds of the committee members are involved in stem cell research and likely to be interested in grants themselves.
For example, the board includes Xiangzhong "Jerry" Yang, the state's premier stem cell researcher. Last year, he threatened to move his work to China if the state did not pass the funding bill. Once he was on the committee, he made it clear that he'd be seeking big bucks. He's now applied for $5 million - from his own committee.
Moreover, because Connecticut has only two research universities, conflicts of interest are built in: Committee...
Related Articles
By Priyanka Runwal, Chemical and Engineering News | 08.05.2024
Saritee Sanodiya, 26, has spent countless days wondering if she’ll ever live a “normal” life. Growing up, Sanodiya often missed school, frequenting the hospital for sudden, life-threatening drops in her hemoglobin levels and excruciating pain in her joints. High fever...
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Sarah Kliff and Azeen Ghorayshi, The New York Times | 07.15.2024